|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia
Alexis A. Thompson,
Jeaniene A. Talley,
Ha Nancy Do,
H. Lee Kagan,
Lori Kunkel,
James Berenson,
Max D. Cooper,
Andrew Saxon, and
Randolph Wall
From the Department of Pediatrics, Division of Hematology/Oncology, Gwynne Hazen Cherry Memorial Laboratories, the Department of Microbiology and Immunology, the Department of Medicine, Divisions of Medical Oncology and Clinical Immunology, UCLA School of Medicine and The Molecular Biology Institute, UCLA, Los Angeles, CA; and the Howard Hughes Medical Institute, University of Alabama at Birmingham, AL.
Leukemic B cells in chronic lymphocytic leukemia (B-CLL) typically exhibit low or undetectable surface Ig. Because the B29 (CD79b and Ig ) and mb-1 (CD79a and Ig ) gene products are required for surface Ig display in the B-cell receptor complex (BCR), we analyzed the expression of these genes in B-CLL cells. The majority (83%) of the randomly selected B-CLL patient samples analyzed exhibited low or undetectable surface BCR measured by µ heavy chain and B29 expression. Levels of mb-1 mRNA in these B-CLL samples with low surface BCR were similar to those in normal B cells. Among those with decreased surface expression, B29 mRNA was not detected in half of these B-CLL samples. The remaining B-CLL samples with diminished surface BCR contained normal levels of B29 mRNA. Further analysis of cDNA clones from the majority of these latter samples contained point mutations, insertions, or deletions that were largely located in the B29 transmembrane and cytoplasmic domains. These results indicate the occurrence of somatic mutations predicted to affect B29 expression and/or function in the majority of B-CLL and suggest that these aberrations underlie the diminished surface BCR display and loss of BCR signaling characteristic of this leukemia.
Blood, Vol. 90 No. 4 (August 15), 1997:
pp. 1387-1394
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Vuillier, G. Dumas, C. Magnac, M.-C. Prevost, A. I. Lalanne, P. Oppezzo, E. Melanitou, G. Dighiero, and B. Payelle-Brogard
Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the {micro} and CD79a chains
Blood,
April 1, 2005;
105(7):
2933 - 2940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nedellec, Y. Renaudineau, A. Bordron, C. Berthou, N. Porakishvili, P. M. Lydyard, J.-O. Pers, and P. Youinou
B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients
J. Immunol.,
March 15, 2005;
174(6):
3749 - 3756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Gordon, C. M. Kanegai, J. R. Doerr, and R. Wall
Somatic hypermutation of the B cell receptor genes B29 (Igbeta , CD79b) and mb1 (Igalpha , CD79a)
PNAS,
April 1, 2003;
100(7):
4126 - 4131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lanham, T. Hamblin, D. Oscier, R. Ibbotson, F. Stevenson, and G. Packham
Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia
Blood,
February 1, 2003;
101(3):
1087 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Cragg, H. T. C. Chan, M. D. Fox, A. Tutt, A. Smith, D. G. Oscier, T. J. Hamblin, and M. J. Glennie
The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis
Blood,
October 16, 2002;
100(9):
3068 - 3076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Matutes
New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders
J. Clin. Pathol.,
March 1, 2002;
55(3):
180 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bernal, R. D. Pastore, Z. Asgary, S. A. Keller, E. Cesarman, H.-C. Liou, and E. J. Schattner
Survival of leukemic B cells promoted by engagement of the antigen receptor
Blood,
November 15, 2001;
98(10):
3050 - 3057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Z. Rassenti and T. J. Kipps
Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion
Blood,
April 15, 2000;
95(8):
2725 - 2727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Payelle-Brogard, C. Magnac, F. R. Mauro, F. Mandelli, and G. Dighiero
Analysis of the B-Cell Receptor B29 (CD79b) Gene in Familial Chronic Lymphocytic Leukemia
Blood,
November 15, 1999;
94(10):
3516 - 3522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Alfarano, S. Indraccolo, P. Circosta, S. Minuzzo, A. Vallario, R. Zamarchi, A. Fregonese, F. Calderazzo, A. Faldella, M. Aragno, et al.
An Alternatively Spliced Form of CD79b Gene May Account for Altered B-Cell Receptor Expression in B-Chronic Lymphocytic Leukemia
Blood,
April 1, 1999;
93(7):
2327 - 2335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Caligaris-Cappio and T. J. Hamblin
B-Cell Chronic Lymphocytic Leukemia: A Bird of a Different Feather
J. Clin. Oncol.,
January 1, 1999;
17(1):
399 - 399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Kim and A. Lerner
Type 4 Cyclic Adenosine Monophosphate Phosphodiesterase as a Therapeutic Target in Chronic Lymphocytic Leukemia
Blood,
October 1, 1998;
92(7):
2484 - 2494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
